In 2022, relatlimab, a monoclonal antibody targeting LAG-3, in combination with Nivolumab, was approved for the treatment of metastatic melanoma, making LAG3 the third clinically utilized immune checkpoint after CTLA-4 and PD-1 (15). This evidence concerns the gene LAG3 and metastatic melanoma.